Jones Day named to the National Law Journal's 2023 "Appellate Hot List"

The National Law Journal named Jones Day to its annual "Appellate Hot List" for 2023. This is the 11th time the Firm has been included on this list.

"Jones Day lawyers make innovative, winning arguments leading to landmark precedents in the Supreme Court and in federal and state appellate courts nationwide," said Traci Lovitt, the leader of Jones Day's Issues & Appeals Practice. "With a consistent presence before the Supreme Court, 14 different Jones Day lawyers have argued 35 cases before the Court over the last decade, and at least three Jones Day lawyers will argue before the Court during the October 2023 term."

During the last term, the Firm won all three of its cases at the Supreme Court, including two unanimous decisions. In Percoco v. United States, the Supreme Court ruled 9-0 in favor of the Firm's client, Joseph Percoco, a former top aide and campaign manager for former New York Governor Andrew Cuomo, in a challenge to his conviction for honest-services fraud arising from conduct when he was a private citizen serving as campaign manager.

The Supreme Court also issued a landmark, favorable ruling for another Firm client in Glacier Northwest, Inc. v. International Brotherhood of Teamsters. There, the Firm successfully argued that the National Labor Relations Act (NLRA) does not impliedly preempt a state tort claim against a union for intentionally destroying an employer's property in the course of labor strike. This decision allows employers to pursue tort claims against unions when property is intentionally endangered during a strike.

And in Lora v. United States, a unanimous decision, Jones Day successfully argued that its client, Efrain Lora, was not subject to a consecutive-sentence mandate.

The Firm's appellate successes extend beyond the Supreme Court. For example, in the U.S. Court of Appeals for the Third Circuit, Jones Day successfully represented a leading global healthcare company in litigation challenging the U.S. Department of Health and Human Services' (HHS) enforcement action under Section 340B of the Public Health Service Act. Section 340B requires pharmaceutical manufacturers participating in Medicare and Medicaid to offer outpatient drugs at discounted prices to certain "covered entities" that provide care for many uninsured or low-income patients.